Particle News: Latest AstraZeneca news

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

Merck plans July shipments of the single-dose antibody ahead of the 2025 RSV season with a CDC advisory review scheduled for late June.

AstraZeneca Cancels £450m UK Vaccine Plant Investment

AstraZeneca Announces $2.5 Billion Beijing R&D Hub to Bolster China Presence

Nvidia Partners with Swedish Consortium to Build Country’s Biggest Enterprise AI Supercomputer

GSK Proposes Doubling CEO Emma Walmsley’s Pay to $27 Million

AstraZeneca Acquires Belgian Biotech EsoBiotec in $1 Billion Deal

CDC Panel Recommends Merck’s Enflonsia Monoclonal Antibody for Babies

Engineered E. Coli Converts Plastic Waste to Paracetamol

NICE Approves Capivasertib for NHS Use in Advanced Breast Cancer Treatment

Tempus AI Surpasses Q1 Expectations, Raises 2025 Revenue Guidance

IonQ to Acquire Oxford Ionics for $1.075 Billion to Expand Quantum Capabilities

AstraZeneca Reports Strong 2024 Results While Facing China Tax Probe

Pharma CEOs Urge EU to Reform Pricing Policies as U.S. Investments Surge

AstraZeneca Cancels £450m UK Vaccine Plant Expansion Over Funding Dispute

AstraZeneca Deepens China Pact With $5.2 Billion CSPC Research Collaboration

UK Finalizes £1bn BioNTech Deal to Advance mRNA Cancer Vaccines and AI Research

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges